Search

Your search keyword '"Billiet, C."' showing total 159 results
Start Over Author "Billiet, C."
159 results on '"Billiet, C."'

1. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group

Author

Ostheimer, C., Mäurer, M., Ebert, N., Schmitt, D., Krug, D., Baumann, R., Henkenberens, C., Giordano, F. A., Sautter, L., López, Guerra, Fleischmann, D. F., Niyazi, M., Käsmann, L., Kaul, D., Thieme, A. H., Billiet, C., Dobiasch, S., Arnold, C. R., Oertel, M., Haussmann, J., Gauer, T., Goy, Y., Suess, C., Ziegler, S., Panje, C. M., Baues, C., Trommer, M., Skripcak, T., and Medenwald, D.

Published
2021
Full Text
View/download PDF

3. Correction to: Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer—results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group

Author

Ostheimer, C., Mäurer, M., Ebert, N., Schmitt, D., Krug, D., Baumann, R., Henkenberens, C., Giordano, F. A., Sautter, L., López, Guerra, Fleischmann, D. F., Niyazi, M., Käsmann, L., Kaul, D., Thieme, A. H., Billiet, C., Dobiasch, S., Arnold, C. R., Oertel, M., Haussmann, J., Gauer, T., Goy, Y., Suess, C., Ziegler, S., Panje, C. M., Baues, C., Trommer, M., Skripcak, T., and Medenwald, D.

Published
2021
Full Text
View/download PDF

6. PO-1383 Neoadjuvant versus definitive chemoradiation for esophageal cancer: a retrospective analysis

Author

Joye, I., primary, Vermeulen, S., additional, Op de Beeck, T., additional, Geudens, N., additional, Vandamme, T., additional, Simoens, M., additional, Botelberge, T., additional, Valk, J., additional, de Maat, M., additional, Lybaert, W., additional, Demey, W., additional, Machiels, M., additional, Nevens, D., additional, Billiet, C., additional, Meijnders, P., additional, Mercier, C., additional, Vanderkam, S., additional, Weytjens, R., additional, and Van Laere, S., additional

Published
2023
Full Text
View/download PDF

7. OC-0270 Metastases-directed SRT and systemic therapy: EORTC-ESTRO OligoCare delphi consensus recommendations

Author

Kroeze, S., primary, Pavic, M., additional, Stellamans, K., additional, Lievens, Y., additional, Becherini, C., additional, Scorsetti, M., additional, Alongi, F., additional, Ricardi, U., additional, Jereczek, B., additional, Westhoff, P., additional, But-Hadzic, J., additional, Widder, J., additional, Geets, X., additional, Bral, S., additional, Lambrecht, M., additional, Billiet, C., additional, Sirak, I., additional, Ramella, S., additional, Battista, I.G., additional, Benavente, S., additional, Zapatero, A., additional, Romero, F., additional, Zilli, T., additional, Khanfir, K., additional, Hemmatazad, H., additional, De Bari, B., additional, Klass, D., additional, Adnan, S., additional, Peulen, H., additional, Salinas Ramos, J., additional, Strijbos, M., additional, Popat, S., additional, Ost, P., additional, and Guckenberger, M., additional

Published
2023
Full Text
View/download PDF

8. Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy: systematic review and consensus recommendations by the EORTC-ESTRO OligoCare consortium.

Author

Kroeze, S.G.C., Pavic, M., Stellamans, K., Lievens, Y., Becherini, C., Scorsetti, M., Alongi, F., Ricardi, U., Jereczek-Fossa, Barbara A., Westhoff, P.G., But-Hadzic, J., Widder, J., Geets, X., Bral, S., Lambrecht, M., Billiet, C., Sirak, I., Ramella, S., Giovanni Battista, I., Benavente, S., Zapatero, A., Romero, F., Zilli, T., Khanfir, K., Hemmatazad, H., Bari, B. De, Klass, D.N., Adnan, S., Peulen, H., Salinas Ramos, J., Strijbos, M., Popat, S., Ost, P., Guckenberger, M., Kroeze, S.G.C., Pavic, M., Stellamans, K., Lievens, Y., Becherini, C., Scorsetti, M., Alongi, F., Ricardi, U., Jereczek-Fossa, Barbara A., Westhoff, P.G., But-Hadzic, J., Widder, J., Geets, X., Bral, S., Lambrecht, M., Billiet, C., Sirak, I., Ramella, S., Giovanni Battista, I., Benavente, S., Zapatero, A., Romero, F., Zilli, T., Khanfir, K., Hemmatazad, H., Bari, B. De, Klass, D.N., Adnan, S., Peulen, H., Salinas Ramos, J., Strijbos, M., Popat, S., Ost, P., and Guckenberger, M.

Abstract

Item does not contain fulltext, Stereotactic body radiotherapy (SBRT) for patients with metastatic cancer, especially when characterised by a low tumour burden (ie, oligometastatic disease), receiving targeted therapy or immunotherapy has become a frequently practised and guideline-supported treatment strategy. Despite the increasing use in routine clinical practice, there is little information on the safety of combining SBRT with modern targeted therapy or immunotherapy and a paucity of high-level evidence to guide clinical management. A systematic literature review was performed to identify the toxicity profiles of combined metastases-directed SBRT and targeted therapy or immunotherapy. These results served as the basis for an international Delphi consensus process among 28 interdisciplinary experts who are members of the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) OligoCare consortium. Consensus was sought about risk mitigation strategies of metastases-directed SBRT combined with targeted therapy or immunotherapy; a potential need for and length of interruption to targeted therapy or immunotherapy around SBRT delivery; and potential adaptations of radiation dose and fractionation. Results of this systematic review and consensus process compile the best available evidence for safe combination of metastases-directed SBRT and targeted therapy or immunotherapy for patients with metastatic or oligometastatic cancer and aim to guide today's clinical practice and the design of future clinical trials.

Published
2023

10. OC-0135 Predicting patient-reported symptom clusters in lung cancer patients: a machine learning approach

Author

Rammant, E., primary, Deman, E., additional, Poppe, L., additional, Billiet, C., additional, Lambrecht, M., additional, Bultijnck, R., additional, Van Hecke, A., additional, Azria, D., additional, Chang-Claude, J., additional, Choudhury, A., additional, De Ruysscher, D., additional, Rosenstein, B., additional, Symonds, P., additional, Valdagni, R., additional, Vega, A., additional, Webb, A., additional, West, C., additional, Fonteyne, V., additional, Veldeman, L., additional, Lievens, Y., additional, and Van Hoecke, S., additional

Published
2022
Full Text
View/download PDF

18. Prognostic impact of gross tumor volume during radical radiochemotherapy of locally advanced non-small cell lung cancer-results from the NCT03055715 multicenter cohort study of the Young DEGRO Trial Group (Jan, 10.1007/s00066-020-01727-4, 2021)

Author

Ostheimer, C., Maeurer, M., Ebert, N., Schmitt, D., Krug, D., Baumann, R., Henkenberens, C., Giordano, F. A., Sautter, L., Lopez, Guerra, Fleischmann, D. F., Niyazi, M., Kaesmann, L., Kaul, D., Thieme, A. H., Billiet, C., Dobiasch, S., Arnold, C. R., Oertel, M., Haussmann, J., Gauer, T., Goy, Y., Suess, C., Ziegler, S., Panje, C. M., Baues, C., Trommer, M., Skripcak, T., Medenwald, D., Ostheimer, C., Maeurer, M., Ebert, N., Schmitt, D., Krug, D., Baumann, R., Henkenberens, C., Giordano, F. A., Sautter, L., Lopez, Guerra, Fleischmann, D. F., Niyazi, M., Kaesmann, L., Kaul, D., Thieme, A. H., Billiet, C., Dobiasch, S., Arnold, C. R., Oertel, M., Haussmann, J., Gauer, T., Goy, Y., Suess, C., Ziegler, S., Panje, C. M., Baues, C., Trommer, M., Skripcak, T., and Medenwald, D.

Published
2021

22. OC-0452: Mature results of a phase I dose-escalation trial of SBRT for bone and lymph node oligometastases

Author

Mercier, C., primary, Claessens, M., additional, De Kerf, G., additional, Gryshkevych, S., additional, Billiet, C., additional, Joye, I., additional, Buys, A., additional, Van Laere, S., additional, Vermeulen, P., additional, Meijnders, P., additional, Löfman, F., additional, Dirix, L., additional, Verellen, D., additional, and Dirix, P., additional

Published
2020
Full Text
View/download PDF

23. Stereotactic ablative body radiotherapy (SABR) combined with Immunotherapy (L19-IL2) in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Author

Lieverse, R., Van, L. E., Oberije, C., Troost, E. G. C., Hadrup, S., Dingemans, A., Hendriks, L., Eckert, F., Hiley, C., Dooms, C., Lievens, Y., De, J. M., Bussink, J., Geets, X., Valentini, V., Elia, G., Nerio, D., Billiet, C., Abdollahi, A., Pasquier, D., Boisselier, P., Yaromina, A., De, R. D., Dubois, L., and Lambin, P.

Subjects
stage IV, phase 2, multicentre, anti-PDL1, Immunotherapy, anti-PD1, L19-IL2, NSCLC, radiotherapy, SABR
Abstract

About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit, and new treatment strategies are therefore still needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-EDB scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR). Within this phase II ImmunoSABR trial, the combination of SABR with or without ICI and the immunocytokine L19-IL2 will be tested as 1st, 2nd or 3rd line treatment in stage IV NSCLC patients. This bi-modal and triple treatment approach is based on the direct cytotoxic effect of radiotherapy, the tumour selective immunocytokine L19-IL2, the abscopal effect observed distant from the irradiated metastatic site(s), and the memory effect. This investigator initiated, multicentric, randomised controlled open-label phase II clinical trial (NCT03705403) will test the hypothesis that the combination of SABR and L19-IL2 increases the progression free survival (PFS) in patients with limited metastatic NSCLC. Patients will be stratified according to their metastatic load (oligo-metastatic: up to 5, or poly-metastatic: 6 to 10 metastases). Patients will be randomised by minimisation to the experimental (E-arm) or the control arm (C-arm). The C-arm will receive SOC, according to the local protocol. E-arm oligo-metastatic patients will receive SABR to all lesions followed by L19-IL2 therapy; radiotherapy for poly-metastatic patients consists of irradiation of at least one (symptomatic) to a maximum of 5 lesions (including ICI in both arms if this is the SOC). ImmunoSABR consists of 14 participating centres located in 6 countries. The accrual period will be 2.5 years, starting after the first centre is initiated and active. Primary endpoint is PFS at 1.5 years based on blinded radiological review, and secondary endpoints are overall survival, toxicity, quality of life and abscopal response. Associative biomarker studies, blood and tumour cell immune monitoring, CT-based radiomics, stool collection, iRECIST, and tumour growth rate will be performed. The first results are expected end 2023.

Published
2020

25. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Author

Lieverse, R.I.Y., Limbergen, E.J. Van, Oberije, C.J.G., Troost, E.G.C., Hadrup, S.R., Dingemans, A.C., Hendriks, L.E., Eckert, F., Hiley, C., Dooms, C., Lievens, Y., Jong, M.C. de, Bussink, J., Geets, X., Valentini, V., Elia, G., Neri, D., Billiet, C., Abdollahi, A., Pasquier, D., Boisselier, P., Yaromina, A., Ruysscher, D. de, Dubois, L.J., Lambin, P., Lieverse, R.I.Y., Limbergen, E.J. Van, Oberije, C.J.G., Troost, E.G.C., Hadrup, S.R., Dingemans, A.C., Hendriks, L.E., Eckert, F., Hiley, C., Dooms, C., Lievens, Y., Jong, M.C. de, Bussink, J., Geets, X., Valentini, V., Elia, G., Neri, D., Billiet, C., Abdollahi, A., Pasquier, D., Boisselier, P., Yaromina, A., Ruysscher, D. de, Dubois, L.J., and Lambin, P.

Abstract

Contains fulltext : 220477.pdf (publisher's version ) (Open Access), BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR). METHODS: This investigator-initiated, multicentric, randomised controlled open-label phase II clinical trial will test the hypothesis that the combination of SABR and L19-IL2 increases progression free survival (PFS) in patients with limited metastatic NSCLC. One hundred twenty-six patients will be stratified according to their metastatic load (oligo-metastatic: ≤5 or poly-metastatic: 6 to 10) and randomised to the experimental-arm (E-arm) or the control-arm (C-arm). The C-arm will receive SOC, according to the local protocol. E-arm oligo-metastatic patients will receive SABR to all lesions followed by L19-IL2 therapy; radiotherapy for poly-metastatic patients consists of irradiation of one (symptomatic) to a maximum of 5 lesions (including ICI in both arms if this is the SOC). The accrual period will be 2.5-years, starting after the first centre is initiated and active. Primary endpoint is PFS at 1.5-years based on blinded radiological review, and secondary endpoints are overall survival, toxicity, quality of life and abscopal response. Associative biomarker studies, immune monitoring, CT-based radiomics, stool collection, iRECIST and tumour growth rate will be performed. DISCUSSION: The combination of SABR with or without ICI and the immunocytokine L19-IL2 will be tested as 1st, 2nd or 3rd li

Published
2020

26. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Author

Lieverse, R.I.Y. (Relinde I Y), Van Limbergen, E.J. (Evert J.), Oberije, C. (Cary), Troost, E.G.C. (Esther G C), Hadrup, S.R. (Sine R.), Dingemans, A.-M.C. (Anne-Marie C), Hendriks, L.E.L. (Lizza E L), Eckert, F. (Franziska), Hiley, C. (Crispin), Dooms, C. (Christophe), Lievens, Y. (Yolande), de Jong, M.C. (Monique C.), Bussink, J. (Johan), Geets, X. (Xavier), Valentini, V. (Vincenzo), Elia, G. (Giuliano), Neri, D. (Dario), Billiet, C. (Charlotte), Abdollahi, A. (Amir), Pasquier, D. (David), Boisselier, P. (Pierre), Yaromina, A. (Ala), Ruysscher, D.K.M. (Dirk) de, Dubois, L., Lambin, P. (Philippe), Lieverse, R.I.Y. (Relinde I Y), Van Limbergen, E.J. (Evert J.), Oberije, C. (Cary), Troost, E.G.C. (Esther G C), Hadrup, S.R. (Sine R.), Dingemans, A.-M.C. (Anne-Marie C), Hendriks, L.E.L. (Lizza E L), Eckert, F. (Franziska), Hiley, C. (Crispin), Dooms, C. (Christophe), Lievens, Y. (Yolande), de Jong, M.C. (Monique C.), Bussink, J. (Johan), Geets, X. (Xavier), Valentini, V. (Vincenzo), Elia, G. (Giuliano), Neri, D. (Dario), Billiet, C. (Charlotte), Abdollahi, A. (Amir), Pasquier, D. (David), Boisselier, P. (Pierre), Yaromina, A. (Ala), Ruysscher, D.K.M. (Dirk) de, Dubois, L., and Lambin, P. (Philippe)

Abstract

BACKGROUND: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR). METHODS: This investigator-initiated, multicentric, randomised controlled open-label phase II clinical trial will test the hypothesis that the combination of SABR and L19-IL2 increases progression free survival (PFS) in patients with limited metastatic NSCLC. One hundred twenty-six patients will be stratified according to their metastatic load (oligo-metastatic: ≤5 or poly-metastatic: 6 to 10) and randomised

Published
2020
Full Text
View/download PDF

27. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled open-label phase II trial

Author

Lieverse, R. I. Y., Van Limbergen, E. J., Oberije, C. J. G., Troost, E. G. C., Hadrup, S. R., Dingemans, A. -M. C., Hendriks, L. E. L., Eckert, F., Hiley, C., Dooms, C., Lievens, Y., De Jong, M. C., Bussink, J., Geets, X., Valentini, Vincenzo, Elia, G., Neri, D., Billiet, C., Abdollahi, A., Pasquier, D., Boisselier, P., Yaromina, A., De Ruysscher, D., Dubois, L. J., Lambin, P., Valentini V. (ORCID:0000-0003-4637-6487), Lieverse, R. I. Y., Van Limbergen, E. J., Oberije, C. J. G., Troost, E. G. C., Hadrup, S. R., Dingemans, A. -M. C., Hendriks, L. E. L., Eckert, F., Hiley, C., Dooms, C., Lievens, Y., De Jong, M. C., Bussink, J., Geets, X., Valentini, Vincenzo, Elia, G., Neri, D., Billiet, C., Abdollahi, A., Pasquier, D., Boisselier, P., Yaromina, A., De Ruysscher, D., Dubois, L. J., Lambin, P., and Valentini V. (ORCID:0000-0003-4637-6487)

Abstract

Background: About 50% of non-small cell lung cancer (NSCLC) patients have metastatic disease at initial diagnosis, which limits their treatment options and, consequently, the 5-year survival rate (15%). Immune checkpoint inhibitors (ICI), either alone or in combination with chemotherapy, have become standard of care (SOC) for most good performance status patients. However, most patients will not obtain long-term benefit and new treatment strategies are therefore needed. We previously demonstrated clinical safety of the tumour-selective immunocytokine L19-IL2, consisting of the anti-ED-B scFv L19 antibody coupled to IL2, combined with stereotactic ablative radiotherapy (SABR). Methods: This investigator-initiated, multicentric, randomised controlled open-label phase II clinical trial will test the hypothesis that the combination of SABR and L19-IL2 increases progression free survival (PFS) in patients with limited metastatic NSCLC. One hundred twenty-six patients will be stratified according to their metastatic load (oligo-metastatic: ≤5 or poly-metastatic: 6 to 10) and randomised to the experimental-arm (E-arm) or the control-arm (C-arm). The C-arm will receive SOC, according to the local protocol. E-arm oligo-metastatic patients will receive SABR to all lesions followed by L19-IL2 therapy; radiotherapy for poly-metastatic patients consists of irradiation of one (symptomatic) to a maximum of 5 lesions (including ICI in both arms if this is the SOC). The accrual period will be 2.5-years, starting after the first centre is initiated and active. Primary endpoint is PFS at 1.5-years based on blinded radiological review, and secondary endpoints are overall survival, toxicity, quality of life and abscopal response. Associative biomarker studies, immune monitoring, CT-based radiomics, stool collection, iRECIST and tumour growth rate will be performed. Discussion: The combination of SABR with or without ICI and the immunocytokine L19-IL2 will be tested as 1st, 2nd or 3rd li

Published
2020

28. Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: a multicentre, randomised controlled open-label phase II trial

Author

Lieverse, RIY, Van Limbergen, EJ, Oberije, CJG, Troost, EGC, Hadrup, SR, Dingemans, AMA, Hendriks, LEL, Eckert, F, Hiley, C, Dooms, C, Lievens, Y, de Jong, M, Bussink, J, Geets, X, Valentini, V, Elia, G, Neri, D, Billiet, C, Abdollahi, A, Du Pasquier, D, Boisselier, P, Yaromina, A, De Ruysscher, D, Dubois, LJ, Lambin, P, Lieverse, RIY, Van Limbergen, EJ, Oberije, CJG, Troost, EGC, Hadrup, SR, Dingemans, AMA, Hendriks, LEL, Eckert, F, Hiley, C, Dooms, C, Lievens, Y, de Jong, M, Bussink, J, Geets, X, Valentini, V, Elia, G, Neri, D, Billiet, C, Abdollahi, A, Du Pasquier, D, Boisselier, P, Yaromina, A, De Ruysscher, D, Dubois, LJ, and Lambin, P

Published
2020

32. PO-0765 Oncological and cosmetic outcome after IOERT as a boost in a large cohort of breast cancer patients.

Author

Machiels, M., primary, Weytjens, R., additional, Erven, K., additional, Westerhoff, J.M., additional, Amrouch, S., additional, Bosiers, J., additional, Verkinderen, L., additional, Hauspy, J., additional, Van Dam, P., additional, Dirix, P., additional, Vos, M., additional, Huget, P., additional, Dirix, L., additional, Meijnders, P., additional, Van Laere, S., additional, Vermeulen, P.B., additional, and Billiet, C., additional

Published
2019
Full Text
View/download PDF

35. Schendingen van de boswetgeving : praktijkgegevens aangaande de feiten en hun sanctionering

Author

Billiet, C. and Billiet, C.

Abstract

In 2009 trad Titel XVI van het decreet van 3 juni 1995 ‘houdende algemene bepalingen inzake milieubeleid’ (DABM) in werking. Deze regelgeving schoeide de handhaving van het Vlaamse milieurecht op een nieuwe leest. Er werd in één uniform sanctioneringsinstrumentarium voorzien, met een opvallende uitbreiding en versterking van de mogelijkheden tot bestuurlijk handhavend optreden, onder meer door de invoering van een bestuurlijk beboetingsstelsel met veralgemeende toepassing. Er werd tevens ingezet op remediërende sanctionering: de remediërende sancties waarover strafrechter en bestuur beschikken, werden aanzienlijk verbeterd. Ook in het Waalse Gewest gebeurde in 2009 een grondige hervorming van het milieuhandhavingsrecht, met vergelijkbare krachtlijnen.

Published
2019

36. OC-0329: Predictive value of GTV in radiotherapy of NSCLC - early results of the NCT03055715 trial

Author

Ostheimer, C., primary, Baues, C., additional, Baumann, R., additional, Billiet, C., additional, Dobiasch, S., additional, Ebert, N., additional, Fleischmann, D., additional, Gauer, T., additional, Goy, Y., additional, Haussmann, J., additional, Henkenberens, C., additional, Kaessmann, L., additional, López guerra, J., additional, Kaul, D., additional, Krug, D., additional, Maeurer, M., additional, Niyazi, M., additional, Oertel, M., additional, Panje, C., additional, Sautter, L., additional, Schmitt, D., additional, Suess, C., additional, Trommer-Nestler, M., additional, Ziegler, S., additional, and Medenwald, D., additional

Published
2018
Full Text
View/download PDF

37. Predictive value of GTV in radiotherapy of NSCLC - early results of the NCT03055715 trial

Author

Ostheimer, C., Baues, C., Baumann, R., Billiet, C., Dobiasch, S., Ebert, N., Fleischmann, D., Gauer, T., Goy, Y., Haussmann, J., Henkenberens, C., Kaessmann, L., Lopez Guerra, J., Kaul, D., Krug, D., Maeurer, M., Niyazi, M., Oertel, M., Panje, C., Sautter, L., Schmitt, D., Suess, C., Trommer-Nestler, M., Ziegler, S., Medenwald, D., Ostheimer, C., Baues, C., Baumann, R., Billiet, C., Dobiasch, S., Ebert, N., Fleischmann, D., Gauer, T., Goy, Y., Haussmann, J., Henkenberens, C., Kaessmann, L., Lopez Guerra, J., Kaul, D., Krug, D., Maeurer, M., Niyazi, M., Oertel, M., Panje, C., Sautter, L., Schmitt, D., Suess, C., Trommer-Nestler, M., Ziegler, S., and Medenwald, D.

Published
2018

38. Acute toxicity in the radical radiotherapy of advanced NSCLC-results of the NCT03055715 trial of the yDEGRO Trial Group

Author

Ostheimer, C., Baues, C., Baumann, R., Billiet, C., Dobiasch, S., Ebert, N., Fleischmann, D. F., Gauer, T., Giordano, F., Goy, Y., Hausmann, J., Henkenberens, C., Kaesmann, L., Guerra, Lopez J. L., Kaul, D., Krug, D., M, Maeurer, Niyazi, M., Oertel, M., Panje, C. M., Pyschny, F., Schmitt, D., Sautter, L., Suess, C., Thieme, A. H., Trommer-Nestler, M., Ziegler, S., Medenwald, D., Ostheimer, C., Baues, C., Baumann, R., Billiet, C., Dobiasch, S., Ebert, N., Fleischmann, D. F., Gauer, T., Giordano, F., Goy, Y., Hausmann, J., Henkenberens, C., Kaesmann, L., Guerra, Lopez J. L., Kaul, D., Krug, D., M, Maeurer, Niyazi, M., Oertel, M., Panje, C. M., Pyschny, F., Schmitt, D., Sautter, L., Suess, C., Thieme, A. H., Trommer-Nestler, M., Ziegler, S., and Medenwald, D.

Published
2018

39. Prognostic and predictive value of GTV in the radical radiotherapy of advanced NSCLC-early results of the NCT03055715 trial of the yDEGRO Trial Group

Author

Ostheimer, C., Baues, C., Baumann, R., Billiet, C., Dobiasch, S., Ebert, N., Fleischmann, D. F., Gauer, T., Giordano, F., Goy, Y., Hausmann, J., Henkenberens, C., Kaesmann, L., Guerra, Lopez J. L., Kaul, D., Krug, D., Maeurer, M., Niyazi, M., Oertel, M., Panje, C. M., Pyschny, F., Schmitt, D., Sautter, L., Suess, C., Thieme, A. H., Trommer-Nestler, M., Ziegler, S., Medenwald, D., Ostheimer, C., Baues, C., Baumann, R., Billiet, C., Dobiasch, S., Ebert, N., Fleischmann, D. F., Gauer, T., Giordano, F., Goy, Y., Hausmann, J., Henkenberens, C., Kaesmann, L., Guerra, Lopez J. L., Kaul, D., Krug, D., Maeurer, M., Niyazi, M., Oertel, M., Panje, C. M., Pyschny, F., Schmitt, D., Sautter, L., Suess, C., Thieme, A. H., Trommer-Nestler, M., Ziegler, S., and Medenwald, D.

Published
2018

49. How to determine fining behaviour in court? Game theoretical and empirical analysis

Author

Rousseau, Sandra and Billiet, C

Subjects
Empirical analysis, Working
Abstract

We build a structural model to understand the fine set in court, which is described as the outcome of a two-stage game between defendant, public prosecutor and judge. The equilibrium fine depends on the harm caused, the costs to society and the probability that the guilty party is punished. This fine influences the severity of prosecution and the defence expenditures. Next we empirically analyse the fines pronounced by the Court of Appeal in Ghent (Belgium) for water related criminal offences. We investigate whether the seriousness of the violation and past convictions, as well as some other characteristics, increase the penalty. ispartof: Working Papers pages:1-39 status: published

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results